Profiel
Neena Kadaba is currently a Director at Eyevensys SAS since 2020.
Prior to this, she worked as a Partner at Mission Bay Capital Management, Inc. from 2014 to 2015.
Dr. Kadaba completed her undergraduate and graduate degrees from Massachusetts Institute of Technology in 2003 and received her doctorate degree from California Institute of Technology in 2008.
Actieve functies van Neena Kadaba
| Bedrijven | Functie | Begin |
|---|---|---|
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Directeur/Bestuurslid | 08-01-2020 |
Eerdere bekende functies van Neena Kadaba
| Bedrijven | Functie | Einde |
|---|---|---|
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital invests in companies located in the United States. The firm focuses on the biotechnology and life sciences sector. It participates in early stage capital transactions. | Private Equity Investor | 31-12-2015 |
Opleiding van Neena Kadaba
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
California Institute of Technology
California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital invests in companies located in the United States. The firm focuses on the biotechnology and life sciences sector. It participates in early stage capital transactions. | Finance |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Commercial Services |
















